Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN55277999
ISRCTN55277999
Completed
N/A

In vivo isolation of circulating tumor cells from peripheral blood of patients with lung cancer by using a structured antibody-coated nanodetector: An explorative mono-center non-randomized blinded trial

GILUPI GmbH (Germany)0 sites60 target enrollmentFebruary 6, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsung cancer (non small cell lung cancer - NSCLC, stage I-IV)CancerMalignanat neoplasm of bronchus or lung, unspecified

Overview

Phase
N/A
Intervention
Not specified
Conditions
ung cancer (non small cell lung cancer - NSCLC, stage I-IV)
Sponsor
GILUPI GmbH (Germany)
Enrollment
60
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 6, 2012
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
GILUPI GmbH (Germany)

Eligibility Criteria

Inclusion Criteria

  • •1\. Subjects suffering from lung cancer (diagnosed), they are qualified for radical operation of the tumor
  • •2\. Age \= 18 years
  • •3\. Results of laboratory tests are in the area that the patient is qualified to perform an operation
  • •4\. Written informed consent
  • •5\. For control group: Five subjects are non\-cancer patients

Exclusion Criteria

  • •1\. Medical history revealing psychiatric disease or any other serious diseases
  • •2\. Participating in other clinical trials
  • •3\. Any findings in physical examination that would in the opinion of the investigator make participation unsafe for the volunteer
  • •4\. Any presence or history of allergy (including hay fever)
  • •5\. Any history of anaphylactic or anaphylactoid
  • •6\. Auto immunological diseases: Anti\-phospholipid antibody syndrome (lupus anticoagulant), Goodpasture's syndrome, lupus erythematosus, relapsing polychondritis, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, antineutrophilic cytoplasmic antibody (ANCA)
  • •7\. Immuno deficiencies: X\-linked aggamaglobulinaemia (XLA), severe combined immunodeficiency (SCID), common variable immunodeficiency (CVID), selective IgA deficiency
  • •8\. Known infection with: hepatitis A, B and C, human immunodeficiency virus (HIV), herpes simplex virus (HSV), cytomegalovirus (CMV), syphilis, toxoplasmosis, tuberculosis; known illegal drug abuse
  • •9\. Changes in laboratory values with negative performance for surgery
  • •10\. Signs of inflammation reactions

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
N/A
In vivo isolation of circulating tumor cells from peripheral blood of patients with breast cancer by using a structured antibody-coated nanodetectorBreast cancer (stage I-IV)CancerMalignant neoplasm of breast
ISRCTN66203697GILUPI GmbH (Germany)78
Completed
N/A
Isolation of circulating tumor cells from the blood of prostate cancer patients using an antibody-coated nanodetectorProstate cancer (all stages), Benign prostatic hyperplasia (all stages)CancerMalignant neoplasm of prostate
ISRCTN10403616GILUPI GmbH (Germany)105
Completed
N/A
Sorting of circulating tumor cells from patients with gastric cancer and genomic DNA extraction: a prospective feasibility studyGastric cancer
JPRN-UMIN000008924Digestive Disease Center, Showa University Northern Yokohama Hospital20
Completed
N/A
Sorting of circulating tumor cells from patients with esophageal cancer and genomic DNA extraction: a prospective feasibility studyEsophageal cancer
JPRN-UMIN000008925Digestive Disease Center, Showa University Northern Yokohama Hospital20
Completed
N/A
Sorting of circulating tumor cells from patients with gastrointestinal stromal tumor and genomic DNA extraction: a prospective feasibility studyGastrointestinal stromal tumor
JPRN-UMIN000008930Digestive Disease Center, Showa University Northern Yokohama Hospital20